- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00764790
Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine Versus a Licensed Comparator in Children
Immunogenicity and Safety of GSK Biologicals' Thimerosal-free TIV Flu Vaccine Versus a Licensed Comparator in Children
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 3
Contacten en locaties
Studie Locaties
-
-
-
Pokfulam, Hongkong
- GSK Investigational Site
-
Shatin, Hongkong
- GSK Investigational Site
-
-
-
-
-
Mexico, Mexico, 6720
- GSK Investigational Site
-
Mexico city, Mexico, 04530
- GSK Investigational Site
-
-
-
-
-
Taipei, Taiwan, 104
- GSK Investigational Site
-
Taipei, Taiwan
- GSK Investigational Site
-
-
-
-
-
Bangkok, Thailand, 10400
- GSK Investigational Site
-
-
-
-
Alabama
-
Birmingham, Alabama, Verenigde Staten, 35244
- GSK Investigational Site
-
Birmingham, Alabama, Verenigde Staten, 35205
- GSK Investigational Site
-
Dothan, Alabama, Verenigde Staten, 36305
- GSK Investigational Site
-
-
Arkansas
-
Benton, Arkansas, Verenigde Staten, 72019
- GSK Investigational Site
-
Conway, Arkansas, Verenigde Staten, 72034
- GSK Investigational Site
-
Fayetteville, Arkansas, Verenigde Staten, 72703
- GSK Investigational Site
-
Jonesboro, Arkansas, Verenigde Staten, 72401
- GSK Investigational Site
-
Little Rock, Arkansas, Verenigde Staten, 72205
- GSK Investigational Site
-
-
California
-
Huntington Beach, California, Verenigde Staten, 92647
- GSK Investigational Site
-
Long Beach, California, Verenigde Staten, 90806
- GSK Investigational Site
-
Paramount, California, Verenigde Staten, 90723
- GSK Investigational Site
-
Sacramento, California, Verenigde Staten, 95816
- GSK Investigational Site
-
San Francisco, California, Verenigde Staten, 94102
- GSK Investigational Site
-
West Covina, California, Verenigde Staten, 91790
- GSK Investigational Site
-
-
Colorado
-
Longmont, Colorado, Verenigde Staten, 80501
- GSK Investigational Site
-
-
Connecticut
-
Norwich, Connecticut, Verenigde Staten, 06360
- GSK Investigational Site
-
-
Idaho
-
Nampa, Idaho, Verenigde Staten, 83686
- GSK Investigational Site
-
-
Illinois
-
DeKalb, Illinois, Verenigde Staten, 60115
- GSK Investigational Site
-
-
Indiana
-
New Albany, Indiana, Verenigde Staten, 47150
- GSK Investigational Site
-
-
Kansas
-
Arkansas City, Kansas, Verenigde Staten, 67005
- GSK Investigational Site
-
Newton, Kansas, Verenigde Staten, 67114
- GSK Investigational Site
-
Wichita, Kansas, Verenigde Staten, 67207
- GSK Investigational Site
-
-
Kentucky
-
Bardstown, Kentucky, Verenigde Staten, 40004
- GSK Investigational Site
-
Louisville, Kentucky, Verenigde Staten, 40207
- GSK Investigational Site
-
-
Louisiana
-
Bossier City, Louisiana, Verenigde Staten, 71111
- GSK Investigational Site
-
Metairie, Louisiana, Verenigde Staten, 70006
- GSK Investigational Site
-
-
Michigan
-
Stevensville, Michigan, Verenigde Staten, 49127
- GSK Investigational Site
-
-
Minnesota
-
Saint Paul, Minnesota, Verenigde Staten, 55108
- GSK Investigational Site
-
-
Missouri
-
Saint Louis, Missouri, Verenigde Staten, 63141
- GSK Investigational Site
-
-
Nebraska
-
Omaha, Nebraska, Verenigde Staten, 68134
- GSK Investigational Site
-
-
Nevada
-
Henderson, Nevada, Verenigde Staten, 89015
- GSK Investigational Site
-
-
New York
-
Cortland, New York, Verenigde Staten, 13045
- GSK Investigational Site
-
-
North Carolina
-
Boone, North Carolina, Verenigde Staten, 28607
- GSK Investigational Site
-
Cary, North Carolina, Verenigde Staten, 27518
- GSK Investigational Site
-
Raleigh, North Carolina, Verenigde Staten, 27609
- GSK Investigational Site
-
-
North Dakota
-
Fargo, North Dakota, Verenigde Staten, 58103
- GSK Investigational Site
-
-
Ohio
-
Austintown, Ohio, Verenigde Staten, 44515
- GSK Investigational Site
-
Cincinnati, Ohio, Verenigde Staten, 45245
- GSK Investigational Site
-
Cleveland, Ohio, Verenigde Staten, 44121
- GSK Investigational Site
-
Dayton, Ohio, Verenigde Staten, 45406
- GSK Investigational Site
-
-
Oregon
-
Gresham, Oregon, Verenigde Staten, 97030
- GSK Investigational Site
-
-
Pennsylvania
-
Erie, Pennsylvania, Verenigde Staten, 16505
- GSK Investigational Site
-
Greenville, Pennsylvania, Verenigde Staten, 16125
- GSK Investigational Site
-
Latrobe, Pennsylvania, Verenigde Staten, 15650
- GSK Investigational Site
-
Pittsburgh, Pennsylvania, Verenigde Staten, 15236
- GSK Investigational Site
-
Uniontown, Pennsylvania, Verenigde Staten, 15401
- GSK Investigational Site
-
Wexford, Pennsylvania, Verenigde Staten, 15090
- GSK Investigational Site
-
-
South Carolina
-
Charleston, South Carolina, Verenigde Staten, 29406
- GSK Investigational Site
-
-
Tennessee
-
Clarksville, Tennessee, Verenigde Staten, 37043
- GSK Investigational Site
-
Jackson, Tennessee, Verenigde Staten, 38305
- GSK Investigational Site
-
Kingsport, Tennessee, Verenigde Staten, 37660
- GSK Investigational Site
-
-
Texas
-
Austin, Texas, Verenigde Staten, 78705
- GSK Investigational Site
-
Fort Worth, Texas, Verenigde Staten, 76135
- GSK Investigational Site
-
Houston, Texas, Verenigde Staten, 77055
- GSK Investigational Site
-
San Angelo, Texas, Verenigde Staten, 76904
- GSK Investigational Site
-
-
Utah
-
Bountiful, Utah, Verenigde Staten, 84010
- GSK Investigational Site
-
Layton, Utah, Verenigde Staten, 84041
- GSK Investigational Site
-
Murray, Utah, Verenigde Staten, 84107
- GSK Investigational Site
-
Provo, Utah, Verenigde Staten, 84604
- GSK Investigational Site
-
Roy, Utah, Verenigde Staten, 84067
- GSK Investigational Site
-
South Jordan, Utah, Verenigde Staten, 84095
- GSK Investigational Site
-
-
Virginia
-
Burke, Virginia, Verenigde Staten, 22015
- GSK Investigational Site
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- A male or female child aged 6 to 35 months at the time of the first vaccination; children who may or may not have had previous administration of influenza vaccine in a previous season are acceptable.
- Subjects having a parent/guardian who the investigator believes can and will comply with the requirements of the protocol.
- Written informed consent obtained from the subject's parent/guardian.
Exclusion Criteria:
- Use of any investigational or non-registered product (drug or vaccine) within 30 days preceding the administration of the study vaccine, or planned use during the study period. Routine, registered childhood vaccinations are not an exclusion criterion.
- History of hypersensitivity to any vaccine.
- History of allergy or reactions likely to be exacerbated by any component of the vaccine.
- Acute disease at the time of enrolment.
- History of Guillain Barré syndrome within 6 weeks of receipt of prior inactivated influenza virus vaccine.
- Receipt of an influenza vaccine outside of this study, during current (2008-09) flu season.
- Administration of immunoglobulins and/or blood products within the 3 months preceding the first dose of study vaccine or planned administration during the study period.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Preventie
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Dubbele
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: Fluarix Dose A Group
Subjects were administered 1 or 2 doses* of Fluarix vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children >12 months of age) or in the anterolateral thigh (children <12 months of age). * Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses. |
One (Day 0) or two (Day 0 and Day 28) doses by intramuscular injection.
Two different doses are tested.
|
Experimenteel: Fluarix Dose B Group
Subjects were administered 1 or 2 doses*, half the volume of dose A, of Fluarix vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children >12 months of age) or in the anterolateral thigh (children <12 months of age). * Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses. |
One (Day 0) or two (Day 0 and Day 28) doses by intramuscular injection.
Two different doses are tested.
|
Actieve vergelijker: Fluzone Group
Subjects were administered 1 or 2 doses* of Fluzone vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children >12 months of age) or in the anterolateral thigh (children <12 months of age). * Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses. |
One (Day 0) or two (Day 0 and Day 28) doses by intramuscular injection.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Geometric Mean Titer (GMT) of Serum Anti-hemagglutinin (HA) Antibodies Against Each of the Influenza Vaccine Strains
Tijdsspanne: Day 0 (PRE), Day 28 or Day 56 (POST)
|
GMTs and their 95% confidence interval are presented for all 3 viral strains comprised in the vaccine. Post-vaccination timepoints: Day 28 for primed or Day 56 for unprimed subjects |
Day 0 (PRE), Day 28 or Day 56 (POST)
|
Number of Subjects Who Seroconverted
Tijdsspanne: Day 28 or Day 56
|
Seroconversion is defined as the number of subjects with either a pre-vaccination anti-HA titer < 1:10 and a post-vaccination titer ≥ 1:40, or a pre-vaccination titer ≥ 1:10 and a minimum 4-fold increase at post-vaccination titer. Post-vaccination timepoints: Day 28 for primed or Day 56 for unprimed subjects |
Day 28 or Day 56
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Number of Seroprotected Subjects
Tijdsspanne: Day 0 (PRE), Day 28 or Day 56 (POST)
|
A seroprotected subject is a subject with a serum anti-HA titer ≥ 1:40 Post-vaccination timepoints: Day 28 for primed or Day 56 for unprimed subjects |
Day 0 (PRE), Day 28 or Day 56 (POST)
|
Seroconversion Factor
Tijdsspanne: Day 28 or Day 56
|
Seroconversion factor is defined as the fold increase in serum anti-HA GMTs post-vaccination (Day 28 or 56) compared to pre-vaccination (Day 0). Post-vaccination timepoints: Day 28 for primed or Day 56 for unprimed subjects |
Day 28 or Day 56
|
Number of Subjects Reporting Solicited Local Symptoms
Tijdsspanne: During a 4-day follow-up period after vaccination
|
Solicited local symptoms assessed include pain, redness and swelling.
|
During a 4-day follow-up period after vaccination
|
Number of Subjects Reporting Solicited General Symptoms
Tijdsspanne: During a 4-day follow-up period after vaccination
|
Solicited general symptoms assessed include drowsiness, irritability, loss of appetitie, and temperature.
|
During a 4-day follow-up period after vaccination
|
Number of Subjects Reporting Unsolicited Adverse Events (AE)
Tijdsspanne: During a 28-day follow-up period after vaccination
|
An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product
|
During a 28-day follow-up period after vaccination
|
Number of Subjects Reporting Serious Adverse Events (SAE) and New Onset of Chronic Diseases (NOCD)
Tijdsspanne: During the entire study (Day 0 until Month 6)
|
An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above. NOCDs assessed include for example: diabetes, asthma, allergies, autoimmune disease, cancer, neuropathic disorders |
During the entire study (Day 0 until Month 6)
|
Number of Subjects Reporting Rare Serious Events
Tijdsspanne: During the entire study (Day 0 until Month 6)
|
Rare serious events have an occurrence rate of 1/300 (0.3%).
|
During the entire study (Day 0 until Month 6)
|
Medewerkers en onderzoekers
Sponsor
Publicaties en nuttige links
Algemene publicaties
- Li-Kim-Moy J, Wood N, Jones C, Macartney K, Booy R. Impact of Fever and Antipyretic Use on Influenza Vaccine Immune Reponses in Children. Pediatr Infect Dis J. 2018 Oct;37(10):971-975. doi: 10.1097/INF.0000000000001949.
- Pavia-Ruz N, Angel Rodriguez Weber M, Lau YL, Nelson EA, Kerdpanich A, Huang LM, Silas P, Qaqundah P, Blatter M, Jeanfreau R, Lei P, Jain V, El Idrissi M, Feng Y, Innis B, Peeters M, Devaster JM. A randomized controlled study to evaluate the immunogenicity of a trivalent inactivated seasonal influenza vaccine at two dosages in children 6 to 35 months of age. Hum Vaccin Immunother. 2013 Sep;9(9):1978-88. doi: 10.4161/hv.25363. Epub 2013 Jun 19.
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 111751
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Bestudeer gegevens/documenten
-
Specificatie gegevensset
Informatie-ID: 111751Informatie opmerkingen: For additional information about this study please refer to the GSK Clinical Study Register
-
Formulier geïnformeerde toestemming
Informatie-ID: 111751Informatie opmerkingen: For additional information about this study please refer to the GSK Clinical Study Register
-
Statistisch analyseplan
Informatie-ID: 111751Informatie opmerkingen: For additional information about this study please refer to the GSK Clinical Study Register
-
Geannoteerd casusrapportformulier
Informatie-ID: 111751Informatie opmerkingen: For additional information about this study please refer to the GSK Clinical Study Register
-
Klinisch onderzoeksrapport
Informatie-ID: 111751Informatie opmerkingen: For additional information about this study please refer to the GSK Clinical Study Register
-
Gegevensset individuele deelnemers
Informatie-ID: 111751Informatie opmerkingen: For additional information about this study please refer to the GSK Clinical Study Register
-
Leerprotocool
Informatie-ID: 111751Informatie opmerkingen: For additional information about this study please refer to the GSK Clinical Study Register
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Influenza
-
Gamaleya Research Institute of Epidemiology and...VoltooidGriep A | Influenza A-virusinfectie | Influenza-epidemie | Influenza H5N1Russische Federatie
-
Vanderbilt University Medical CenterHuman Vaccines ProjectVoltooidVaccin reactie | Influenza | Influenza, mens | Griep A | Influenza type B | Influenza A H3N2 | Influenza A H1N1Verenigde Staten
-
NPO PetrovaxVoltooidVaccin reactie | Influenza | Influenza, mens | Griep A | Acute luchtweginfectie | Influenza type B | Griep | Influenza A H3N2 | Influenza A H1N1 | Griep, mens | Influenza-epidemieRussische Federatie
-
Quidel CorporationVoltooidInfluenza A, Influenza BVerenigde Staten
-
Vaxine Pty LtdAustralian Respiratory and Sleep Medicine InstituteVoltooid
-
Ology BioservicesVoltooidInfluenza, vogelAustralië, Finland, Singapore, Spanje
-
Henry M. Jackson Foundation for the Advancement...National Institute of Allergy and Infectious Diseases (NIAID); Food and Drug... en andere medewerkersActief, niet wervendInfluenza | Influenza-achtige ziekte | Influenza vaccinsVerenigde Staten
-
AVIR Green Hills Biotechnology AGVoltooidInfluenza, vogelRussische Federatie
-
National Institute of Allergy and Infectious Diseases...Voltooid
-
National Institute of Allergy and Infectious Diseases...Voltooid
Klinische onderzoeken op Fluarix
-
GlaxoSmithKlineVoltooid
-
GlaxoSmithKlineVoltooid
-
GlaxoSmithKlineVoltooid
-
National Institute of Allergy and Infectious Diseases...Voltooid
-
GlaxoSmithKlineVoltooidInfluenzaAustralië, Brazilië
-
GlaxoSmithKlineVoltooid
-
Northwestern UniversityVoltooid
-
Emory UniversityBeëindigd
-
GlaxoSmithKlineVoltooidInfluenzaVerenigde Staten, Duitsland, Polen, Nederland
-
GlaxoSmithKlineVoltooid